Skip to main content
    S

    Stoke Therapeutics Inc (STOK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $26.41
    -0.22 (-0.83%)

    Market Cap: $1.74B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Stoke Therapeutics Inc (STOK) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Stoke Therapeutics (STOK) has a market cap of $1.74B and an enterprise value of $1.63B. It kept -862.07% of revenue as net income over the last 12 months. Revenue fell 86.28% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 6.16% below the market cap, as cash exceeds debt.

    Market Cap$1.74B
    Enterprise Value$1.63B
    Latest price (Nov 17, 2026)$26.41

    Key Dates

    The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 15, 2027 (expected)
    Last Earnings DateOct 29, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 3.55% in the quarter ended Sep 30, 2026 and grew 10.15% a year over 2 years.

    Shares Outstanding68.36M
    Shares Change (YoY)+16.64%
    Shares Change (QoQ)+3.55%
    Share Count Growth (2Y CAGR)+10.15%

    Valuation Ratios

    Sales and book value multiples are 64.0x and 5.1x. Its year-end P/S ranged from 10.0x to 28.9x from 2022 to 2025.

    P/S Ratio64.0x
    Forward P/S50.2x
    P/B Ratio5.1x

    Valuation history and multiples

    Price Statistics

    The stock is down 0.38% over 52 weeks and trades 0.34% above its 50-day average.

    Beta (1Y)1.00
    52-Week Change-0.38%
    1-Month Change+6.41%
    3-Month Change-20.04%
    6-Month Change-11.85%
    5-Year Change+15.16%
    Total Return (1Y)-0.38%
    Total Return (3Y CAGR)+84.26%
    Total Return (5Y CAGR)-1.21%
    Return vs SPY (1Y)-20.24%
    Max Drawdown (1Y)-41.33%
    Max Drawdown (3Y)-66.32%
    Sharpe Ratio (1Y)-0.17
    Correlation with SPY (1Y)0.26
    50-Day Average$26.32
    200-Day Average$30.75
    52-Week Range$22.05 to $40.22
    RSI (14 Days)49.7
    Average Volume (20 Days)1.26M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.24x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio7.24x
    Quick Ratio7.24x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -68.98% over the last 12 months, against a 5-year average of -40.10%.

    Return on Equity (ROE)-68.98%
    Return on Assets (ROA)-59.80%
    ROE (5Y Average)-40.10%
    ROA (5Y Average)-31.13%
    ROIC (5Y Average)-4.63%
    Asset Turnover0.07x
    Receivables Turnover3.59x

    Scores

    STOK has an Altman Z-Score of 16.55, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score16.55
    Altman Z ZoneSafe
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $28.21M over the last 12 months.

    Revenue$28.21M
    Revenue Growth (YoY)-86.28%
    Gross Profit$28.21M
    Operating Income-$257.60M
    Pretax Income-$243.20M
    Net Income-$243.20M
    Reported EPS (TTM)-$3.77

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 86.70% of the $406.69M in total assets.

    Cash and Equivalents$107.27M
    Total Debt$0
    Net Cash$107.27M
    Net Cash Per Share$1.57
    Working Capital$305.44M
    Shareholder Equity$352.59M
    Book Value Per Share$5.16
    Total Assets$406.69M
    Total Liabilities$54.10M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $5.41M of capital spending, operating cash flow left -$215.72M of free cash flow.

    Operating Cash Flow-$210.31M
    Capital Expenditures$5.41M
    Free Cash Flow-$215.72M
    FCF Per Share-$3.33
    Depreciation and Amortization$3.39M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -913.12%.

    Gross Margin100.00%
    Operating Margin-913.12%
    Pretax Margin-862.07%
    Net Margin-862.07%
    FCF Margin-764.66%

    Growth

    Revenue grew 145.89% a year over 3 years.

    Revenue Growth (3Y CAGR)+145.89%
    Book Value Per Share Growth (2Y CAGR)+30.41%
    Tangible Book Per Share Growth (2Y CAGR)+30.41%

    Revenue and profit by year

    Dividends and Yields

    STOK does not pay a dividend. Its free cash flow yield is -11.95%.

    FCF Yield-11.95%
    Buyback Yield-8.18%
    Shareholder Yield-8.18%

    Peer Position

    Against 6 similar companies, STOK has the 3rd highest P/S.

    P/S Ratio64.0x vs 11.1x median
    Revenue Growth (Trailing 4 Quarters, YoY)-86.28% vs -59.47% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -47.57% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-47.57%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About STOK

    What is STOK's market cap?

    Stoke Therapeutics has a market cap of $1.74B. Its enterprise value, which adds debt and subtracts cash, is $1.63B.

    How many shares of STOK are outstanding?

    Stoke Therapeutics has 68.36M shares outstanding. The count is up 16.64% from a year earlier.

    Does STOK pay a dividend?

    No. Stoke Therapeutics does not pay a dividend.

    How much debt does STOK have?

    Stoke Therapeutics has $0 of total debt and $107.27M of cash and equivalents, a net cash position of $107.27M.